MPSLTD MPS Q1 FY27 results (Apr–Jun 2026) and concall
MPS Limited delivered a strong Q1 FY27, marked by robust revenue growth of 20.4% and a significant 53.0% increase in EBITDA, with margins expanding to 34.3%. The company achieved a 'Rule of 50' score of 54%, reflecting effective operating leverage and a strategic shift towards outcomes-based revenue. Key segments like Education and Corporate Learning showed strong performance and margin improvement, while the Unbound Medicine acquisition is integrating well and contributing to predictable revenue streams. Management reaffirmed its FY27 EBITDA target of over INR 300 crores, expressing high conv
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 24.0%, net profit up 41.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 87 | 90 | 94 | 100 | 111 +28% | 108 +20% | 119 +27% | 124 +24% |
| EBITDA | 35 | 34 | 35 | 34 | 44 +26% | 41 +21% | 48 +37% | 54 +59% |
| Net profit | 27 | 29 | 27 | 29 | 30 +11% | 25 −14% | 44 +63% | 41 +41% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.





